Skip to Main Content

INFORMATION FOR

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)

Conditions

Children's Health | Headaches

Phase III

What is the purpose of this trial?

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

  • Trial with
    Eli Lilly and Company
  • Start Date
    03/02/2021
  • End Date
    08/30/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/22/2022
  • Study HIC
    #2000028680